Bicycle Therapeutics (BCYC) Assets Average (2019 - 2026)
Bicycle Therapeutics' (BCYC) quarterly Assets Average came in at $629.5 million in Q2 2026, down 26.64% YoY from $858.0 million in Q2 2025, and down 8.1% on a QoQ basis from $685.0 million in Q1 2026.
Bicycle Therapeutics (BCYC) Assets Average (2019 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 8 years of Assets Average data on file, last reported at $629.5 million in Q2 2026.
- Quarterly Assets Average fell 26.64% year-over-year to $629.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $629.5 million (down 26.64% YoY) and the FY2025 annual result came in at $837.2 million, up 7.88% from the prior year.
- Assets Average retreated to $629.5 million in Q2 2026, from $685.0 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $1.0 billion in Q3 2024 to a low of $413.9 million in Q4 2022.
- A 5-year average of $655.6 million and a median of $623.3 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average jumped 143.99% — and 2026, when it decreased 26.64%.
- Tracing BCYC's Assets Average over 5 years: stood at $413.9 million in 2022, then jumped by 49.08% to $617.0 million in 2023, then jumped by 58.31% to $976.8 million in 2024, then retreated by 24.16% to $740.8 million in 2025, then decreased by 15.02% to $629.5 million in 2026.
- The last three Assets Average figures came in at $629.5 million (Q2 2026), $685.0 million (Q1 2026), and $740.8 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | 629.49 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 629.49 Mn |
| Mar 31, 2026 | 685.00 Mn |
| Dec 31, 2025 | 740.78 Mn |
| Sep 30, 2025 | 798.07 Mn |
| Jun 30, 2025 | 858.04 Mn |
| Mar 31, 2025 | 920.38 Mn |
| Dec 31, 2024 | 976.81 Mn |
| Sep 30, 2024 | 1.03 Bn |
| Jun 30, 2024 | 802.25 Mn |
| Mar 31, 2024 | 571.24 Mn |
| Dec 31, 2023 | 617.01 Mn |
| Sep 30, 2023 | 546.43 Mn |
| Jun 30, 2023 | 441.49 Mn |
| Mar 31, 2023 | 419.71 Mn |
| Dec 31, 2022 | 413.88 Mn |
| Sep 30, 2022 | 431.32 Mn |
| Jun 30, 2022 | 452.52 Mn |
| Mar 31, 2022 | 469.68 Mn |
| Dec 31, 2021 | 380.56 Mn |
| Sep 30, 2021 | 253.69 Mn |